Kandoset (Amlodipine, Candesartan Cilexetil)

Amlodipine blocks calcium entry into vascular smooth‑muscle cells, causing arterial dilation. Candesartan cilexetil is converted to candesartan, which blocks AT1 angiotensin‑II receptors, preventing vasoconstriction and aldosterone release. Together they provide complementary blood‑pressure‑lowering effects.

The appropriate dose of Kandoset is determined by the prescribing clinician based on the individual’s blood‑pressure profile, renal and hepatic function, and concomitant therapies. Patients should follow the exact regimen written on their prescription and not adjust the dose on their own.

Safety of Kandoset in pregnancy and lactation has not been established. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and typically it is avoided in pregnant or nursing women unless no suitable alternatives exist.

To order Kandoset, submit an enquiry on the product page at gnhindia.com indicating the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Kandoset combines a calcium‑channel blocker and an angiotensin‑II receptor blocker, offering additive blood‑pressure reduction compared with using either class alone. This dual‑action approach can achieve target pressures with fewer tablets than separate agents, but individual tolerability and drug‑interaction profiles still need consideration.

Kandoset tablets should be stored at ambient temperature, preferably below 25 °C, in the original container to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Kandoset is taken orally, usually once daily, with or without food. The tablet should be swallowed whole with a full glass of water. Patients should not crush, chew, or split the tablet unless specifically instructed by their healthcare provider.

Serious risks include symptomatic hypotension, especially in patients who are volume‑depleted or taking other antihypertensives, and angio‑edema, which can be life‑threatening. Liver enzyme elevations and severe allergic reactions are also possible, requiring immediate medical attention.

Kandoset is contraindicated in patients with known hypersensitivity to amlodipine, candesartan or any excipients, and in those with severe hepatic impairment. Caution is advised in patients with significant renal dysfunction, uncontrolled heart failure, or a history of angio‑edema.